Catecholaminergic Polymorphic Ventricular Tachycardia — Exertional Syncope & Sudden Death Prevention

Key Points

• Exercise- or emotion-triggered syncope with a normal resting ECG should raise suspicion for CPVT.
• Bidirectional VT is a classic but not exclusive arrhythmic pattern.
• Exercise testing is a core diagnostic and treatment-monitoring tool.
• Nadolol or propranolol is preferred over selective beta-blockers when tolerated.
• Flecainide is added for persistent ventricular ectopy or symptoms despite beta-blockade.
• Left cardiac sympathetic denervation is an important escalation option.
• ICDs can save lives but shocks may increase catecholamines and trigger further arrhythmia.
• Genetic testing enables cascade screening of relatives.

Algorithm

1. Recognize exertional/emotion-triggered syncope, seizure-like events, palpitations, or arrest in a structurally normal heart.
2. Obtain resting ECG, echocardiography, and family history of sudden death or exertional syncope.
3. Perform supervised exercise stress testing to look for adrenergically induced ventricular ectopy or bidirectional/polymorphic VT.
4. Order inherited-arrhythmia genetic testing when CPVT is clinically suspected.
5. Start nadolol or propranolol and counsel against strenuous/competitive exercise pending expert assessment.
6. Repeat exercise testing to assess suppression and adherence.
7. Add flecainide if ventricular ectopy or symptoms persist.
8. Consider LCSD and selective ICD therapy for refractory disease or prior cardiac arrest, with expert programming and follow-up.

Clinical Synopsis & Reasoning

CPVT should be suspected in a child, adolescent, or young adult with syncope, presyncope, palpitations, seizure-like episodes, or cardiac arrest during exercise or intense emotion, particularly when the resting ECG and echocardiogram are normal. The hallmark is catecholamine-triggered ventricular ectopy that can progress from isolated premature ventricular beats to bigeminy, couplets, bidirectional VT, polymorphic VT, and ventricular fibrillation as heart rate rises.

The most common genetic cause is an autosomal dominant pathogenic variant in RYR2, which disrupts calcium handling in the cardiac ryanodine receptor. Recessive and rarer forms involve CASQ2 and other calcium-handling genes. The resting QT interval is generally normal, distinguishing CPVT from long-QT syndromes. Structural imaging is usually normal. The diagnosis is often delayed because exertional syncope is attributed to vasovagal episodes, dehydration, epilepsy, or anxiety.

Exercise testing is the central provocative test because arrhythmias usually emerge reproducibly with increasing adrenergic drive. A typical progression from ventricular ectopy to bidirectional or polymorphic VT strongly supports the diagnosis. Ambulatory monitoring can capture spontaneous events, but a normal monitor does not exclude CPVT. Epinephrine challenge is sometimes used when exercise is impossible, though specialized interpretation is required. Genetic testing is recommended when the clinical phenotype is strong and enables cascade screening of relatives.

The critical reasoning distinction is that an apparently “normal ECG” does not make this low risk. CPVT is a channelopathy of triggered intracellular calcium release rather than a resting depolarization/repolarization abnormality. Another key point is that painful ICD shocks can provoke further catecholamine release and arrhythmia, so device therapy must be integrated with aggressive antiadrenergic treatment rather than used as a stand-alone solution.

Treatment Strategy & Disposition

Treatment aims to suppress adrenergically triggered ventricular arrhythmias and prevent sudden death. Nonselective beta-blockers, particularly nadolol or propranolol, are preferred first-line agents. Dosing is pushed toward the highest tolerated level, and adherence is critical because even a missed dose can expose the patient to substantial risk. Patients should avoid competitive sports, strenuous exercise, and highly adrenergic situations unless an expert inherited-arrhythmia team has established a safer individualized plan.

Flecainide is added when ventricular ectopy, bidirectional/polymorphic VT, exertional symptoms, or syncope persists despite beta-blocker therapy. It reduces triggered calcium release and can substantially improve exercise-test suppression. Treatment effectiveness should be reassessed with repeat exercise testing rather than inferred solely from symptom absence.

Left cardiac sympathetic denervation is an important option for patients with recurrent syncope or ventricular arrhythmias despite optimized beta-blocker plus flecainide therapy, or when beta-blockers are not tolerated. ICD therapy is indicated in selected high-risk patients, especially survivors of cardiac arrest or those with refractory malignant arrhythmias, but it requires careful programming and concomitant drug therapy because shocks can trigger electrical storm in CPVT.

Family screening is part of treatment. First-degree relatives should undergo clinical assessment and genetic testing when a pathogenic family variant is known. Patients require counseling about exercise, medication adherence, interacting drugs, pregnancy, and emergency planning. Acute unstable VT/VF is treated with standard resuscitation, but the chronic strategy is antiadrenergic and mechanism-specific.

Epidemiology / Risk Factors

• CPVT usually presents in childhood or adolescence but can present in adults.
• RYR2-mediated autosomal dominant disease is the most common form.
• Sudden cardiac death may be the first manifestation in an undiagnosed patient.
• Family history can be negative because de novo variants and variable penetrance occur.

Investigations

CPVT vs Common Mimics

Pharmacology

Prognosis / Complications

• Untreated CPVT carries a high risk of recurrent syncope, cardiac arrest, and sudden death.
• Appropriate beta-blockade substantially reduces risk but does not eliminate it.
• Flecainide and LCSD can further reduce breakthrough arrhythmia.
• Long-term outcome depends heavily on adherence and expert follow-up.

Patient Education / Counseling

• Explain that the resting ECG can be normal even though dangerous exercise-triggered arrhythmias are possible.
• Emphasize taking every beta-blocker dose and never stopping therapy abruptly without specialist guidance.
• Provide individualized activity restrictions and emergency planning for school, sports, and work.
• Encourage family genetic testing and cardiac evaluation.
• Discuss ICD benefits and limitations clearly if device therapy is being considered.

Notes

CPVT is a high-yield example of why a normal resting test cannot substitute for understanding physiology. The dangerous abnormality appears under catecholaminergic stress. The best clue is not the resting ECG; it is the reproducible relationship between exertion or emotion and ventricular arrhythmia.

Treatment is equally mechanism-specific. Nonselective beta-blockade, flecainide, and sympathetic denervation reduce the trigger pathway. An ICD can be lifesaving in selected patients, but it is not benign in CPVT because shocks can amplify adrenergic drive. The safest management is therefore layered rather than device-only.

References

1. GeneReviews — Catecholaminergic Polymorphic Ventricular Tachycardia — Link
2. Spotlight on the 2022 ESC guideline for ventricular arrhythmias and sudden cardiac death — Link
3. 2022 ESC Guideline recommendations for CPVT (Oxford Academic table) — Link